CClinicalTrials.gg
WithdrawnNCT01958242Updated Nov 24, 2015

Effect of Blood Harvesting and Administration at End of CPB on Coagulation Profile

An interventional study of Preoperative blood harvesting in Hematologic Changes, sponsored by Rabin Medical Center. Withdrawn at 1 site in Israel. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2015-11-24.

Sponsored by Rabin Medical Center · Not applicable, Interventional, and Diagnostic

Why this study was withdrawn
Technical problems.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
Up to 18 Years
Sex
All
01

Study summary

Blood transfusions after pediatric heart surgery is a relatively common practice occurring in up to 46% of patients, however its use has been associated with increased morbidity. In the pediatric population undergoing heart surgery transfusion of homologous blood is usually required due to the mismatch between the priming volume of the cardiopulmonary bypass circuit and the patients own blood volume. Several strategies have been proposed in order to minimize the use of blood products. The effect of pre-operative harvest of fresh whole blood in the adult population has shown a beneficial platelet protective effect, however concerns have been risen that the amount of volume needed in order to sequester a significant amount of platelets would be prohibit ally high in a cardiac surgical patient. Fresh blood harvesting has not been evaluated in the pediatric population.

The purpose of the present study would be to evaluate the safety and efficacy of pre-operative blood harvesting in the pediatric population undergoing open heart surgery. Fresh whole blood will be harvested from the patient prior to the initiation of cardiopulmonary bypass and will be returned to the patient after the discontinuation of CPB prior to the administration of prominent. Parameters that will be evaluated will include, patient characteristic, operative and post-operative parameters, coagulation profiles and the use of postoperative blood products.

Read the detailed description

All pediatric patients undergoing open heart surgery at our institution will be randomized based on the last digit of their identification number (even or odd numbers) to undergo pre-operative whole blood harvesting (PBH). Informed consent will be obtained from the parents at the time of surgical informed consent acquisition.

After scrubbing and draping of the patient the first set of blood samples will be obtained for baseline.

Circuit priming will be performed using plasmalyte , and the prime will be adjusted to have a calculated bypass hematologic 27%, taking into consideration the amount of blood harvested.

Once the patient is connected to the CPB circuit, harvested blood will be taken from the venous line before its passage through the oxygenator, while crystalloids from the circuit will be infused through the arterial line in order to maintain adequate blood pressure. Once the amount of 15cc/kg of blood is harvested, CPB will be initiated and the operation will be carried out in the usual manner. Blood will be kept at room temperature (18°C), gently stirred (not shaken).

At the end of the operation, veno-venous ultrafiltration will be performed, targeting a duration of 10 minutes. The harvested blood will be administered at the end of ultrafiltration in conjunction to the administration of protamine. Blood samples will be obtained at various time points. Complete blood count, coagulation profile (PT/PTT), and platelet function tests will be performed. Pre-operative and operative characteristics will be recorded .

In the intensive care unit, the patient will be continuously followed until his discharge from the hospital and post-operative parameters will be recorded. Blood and blood product administration will be based on our ICU protocol and at the discretion of the attending physician. Generally, blood will be administered to single ventricle patients if their hemoglobin levels will be below 12 mg%, while in the 2 ventricle patients a threshold of 9mg% will be set. Administration of blood products will be performed if there will be signs of clinical bleeding with overt signs of coagulopathy (INR > 2, fibrinogen \< 100, platelets \< 50,000).

02

Conditions studied

  • Hematologic Changes

Keywords

  • Cardiopulmonary bypass
  • pediatric
  • blood products
  • conservation
03

In context

Lead sponsor

Rabin Medical Center is the lead sponsor of 385 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • All pediatric patients undergoing heart surgery

Exclusion criteria

Exclusion Criteria:

  • Unstable patients
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • No intervention
    Preoperative blood harvesting

    Other: Preoperative blood harvesting

Interventions

  • OtherPreoperative blood harvesting

    There is no true intervention, there is a protocol of preoperative blood harvesting ,and post operative administration of the same blood/

06

What researchers measure

Primary outcomes

  1. Improvement in coagulation profile

    Coagulation studies will be measured before and after the intervention

    Time frame: Immediate post operative

07

Study locations

1 site
  • Schneider Children Medical center of Israel
    Petah Tikva, 49202, Israel
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01958242
Lead sponsor
Rabin Medical Center
Responsible party
Sponsor
First posted
Oct 9, 2013
Start date
Jan 2014
Primary completion
Dec 2015 (estimated)
Completion
Dec 2015 (estimated)
Last update
Nov 24, 2015

Study contacts

Gabriel Amir, MD
principal investigator · SCMCI

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion